 Ligand Pharmaceuticals NASDAQ:LGND had its target price upped by Benchmark from 135.00 to 155.00 in a research report issued on Tuesday, The Fly reports. The firm currently has a buy rating on the biotechnology companys stock. Benchmarks price objective suggests a potential upside of 29.79 from the stocks current price. LGND has been the subject ... 